is an outer mitochondrial membrane-bound enzyme that catalyzes the oxidative deamination of arylalkylamine neurotransmitters and has been a target for a number of clinically used drug inhibitors. The 1.7-Å structure of the reversible isatin-MAO-B complex has been determined; it forms a basis for the interpretation of the enzyme's structure when bound to either reversible or irreversible inhibitors. 1,4-Diphenyl-2-butene is found to be a reversible MAO-B inhibitor, which occupies both the entrance and substrate cavity space in the enzyme. 
T he structure and function of monoamine oxidases A and B (MAO-A and -B) have been of interest to a wide variety of scientific disciplines because of the role of these enzymes in the oxidation of arylalkylamine neurotransmitters such as dopamine and serotonin. The proposed role of MAO-B in age-dependent neurodegenerative diseases has resulted in a renewed interest in this enzyme as a target for the development of neuroprotective agents. MAO-B inhibitors are used clinically and others are in development. MAO-A and -B have been extensively investigated and serve as the prototype for the flavin-dependent amine oxidases.
The recent description of the 3.0-Å structure of human recombinant MAO-B in its pargyline-inhibited form by our laboratories (1) revealed a two-domain architecture of the molecule and its mode of binding to the mitochondrial outer membrane through a C-terminal hydrophobic ␣-helix. These studies show the substrate negotiates a protein loop in its entry into the active site of the enzyme, which involves traversing an ''entrance cavity'' before entering the ''substrate cavity'' (Fig. 1) .
We report here the structures of MAO-B in complex with several reversible and irreversible inhibitors (Fig. 2) to elucidate their respective binding modes as well as to provide insights into the mode of inhibition. Higher (1.7 Å) resolution data were obtained that provide additional structural details on the active site relevant to drug design and to the detailed catalytic mechanism.
The structure of MAO-B in complex with isatin was determined because this compound is found at higher levels in patients with neuropathological conditions and has been shown to be a competitive MAO-B inhibitor with a K i of 3 M (2). In the course of these studies, we have uncovered a competitive MAO-B inhibitor (K i ϭ 35 M) that is identified as 1,4-diphenyl-2-butene, a contaminant of polystyrene products (3) .
The structure of MAO-B after inhibition with N-(2-aminoethyl)-p-chlorobenzamide (also known as Ro 16-6491) was elucidated. This compound belongs to a class of highly specific MAO-B inhibitors, which includes lazabemide. A previous study (4) suggested this inhibitor binds to a site on the enzyme other than the flavin moiety. Tranylcypromine (trans-2-phenylcyclopropylamine) has been known for Ͼ40 years as a MAO inhibitor and used clinically as an antidepressant. As with the lazabemide class of inhibitors, tranylcypromine has been thought to exert its inhibitory action as a mechanism-based inhibitor by covalent binding of the MAO-B-catalyzed reaction product to an amino acid side chain (5, 6) . The structural data presented in this study show that, in contrast to previous conclusions, tranylcypromine and N-(2-aminoethyl)-p-chlorobenzamide inhibit MAO-B by covalent binding to the flavin ring, however, at differing sites on the isoalloxazine ring.
Materials and Methods
Expression, purification, absorption spectral studies, and catalytic assays of recombinant human liver MAO-B were performed as described (7) . All chemicals used in this study were obtained from commercial sources.
Orthorhombic MAO-B crystals were grown by the sitting-drop vapor diffusion method at 4°C (1) using polystyrene microbridges obtained from Hampton Research. The precipitant solution consisted of 12% (wt͞vol) PEG 4000, 70 mM lithium sulfate, and 100 mM N-(2-acetamido)-2-iminodiacetic acid (ADA), pH 6.5. The protein solution contained 2 mg of MAO-B per ml, 8.5 mM Zwittergent 3-12, and 25 mM potassium phosphate buffer, pH 7.5. Crystals of enzyme-inhibitor complexes were obtained by incubating the protein with 2 mM inhibitor followed by gel filtration on Superdex 200. For all Abbreviation: MAO, monoamine oxidase.
Data deposition: The atomic coordinates and the structure factors have been deposited in the Protein Data Bank, www.rcsb.org (PBD ID codes 1OJA, 1OJB, 1OJC, 1OJD, and 1OJ9).
inhibitors except tranylcypromine, 2 mM inhibitor was added to the crystallization drop. Triclinic crystals were grown as described (1). X-ray diffraction data were collected at 100 K at the Swiss Light Source in Villigen and at the beam-line ID14-EH4 of the European Synchrotron Radiation Facility in Grenoble, France. The high brilliance provided by these beam-lines resulted in a significant increase of the resolution of the diffraction data. The diffraction images were processed with MOSFLM (8) and programs of the CCP4 package (9) .
Structure refinements were performed with the programs REFMAC5 (10) and WARP (11) . Tight noncrystallographic symmetry restraints were applied throughout the refinements. The atomic models were built with program O (12) . Unbiased 2F o Ϫ F c and F o Ϫ F c maps were used to model the inhibitors which, in all cases, were well defined by the electron density maps (Fig. 3) . The models exhibit good stereochemical parameters with only three residues in each monomer (Lys-52, Ala 346, and Asp 419) in disallowed regions of the Ramachandran plot. The refinement statistics are listed in Table 1 . Analysis of the final models were carried out with the programs GRID (13) and VOIDOO (14) . Pictures were produced by using LIGPLOT (15) , BOBSCRIPT (16) , MOLSCRIPT (17) , and RASTER3D (18) .
Results and Discussion
Structural Analysis of Reversible, Noncovalent Inhibitor-MAO-B Complexes. The tight, reversible binding of isatin ( Fig. 2) to MAO-B has been known since its original identification (2) . Isatin competitively binds to purified, recombinant MAO-B with a K i of Ϸ3 M. The tight binding of the inhibitor led to an improved crystal quality and diffraction data could be measured up to 1.7-Å resolution (Table 1) . A stereoview of this structure is shown in Fig. 3 . The electron density of the dioxoindole ring shows its orientation in the substrate cavity to be perpendicular to the f lavin ring with the oxo groups on the pyrrole ring pointing toward the f lavin. The 2-oxo group and the pyrrole NH are H-bonded to ordered water molecules present in the active site, whereas the 3-oxo function is not involved in any H-bond. The balance of the binding interactions involve many van der Waals contacts between the isatin ring and amino acid residues in the solvent-inaccessible, hydrophobic substrate cavity.
An unanticipated noncovalent inhibitor of MAO-B was serendipitously discovered when we attempted to determine the structure of the enzyme in the presence of d-amphetamine. Rather than containing amphetamine, the crystals were found to contain 1,4-diphenyl-2-butene (whose identification will be detailed in a separate communication, ref.
3). The source of this compound was found to be an impurity released by the polystyrene microbridges used for crystallization of the enzyme. We find that this compound competitively binds to MAO-B (K i Ϸ 35 M). Its presence does not interfere with structure determinations of MAO-B in complex with other inhibitors that have higher binding affinities or are covalently bound. The novel aspect of this inhibitor is that it is bound in a manner where one phenyl ring is in the entrance cavity space whereas the other phenyl ring is in the substrate cavity space (Figs. 1 and 4 ) overlapping the position occupied by isatin. The planes of the two phenyl rings of this inhibitor are orthogonal to one another.
In this structure, the two cavities are now fused into one single cavity, which constitutes a significant proportion of the volume of the protein (Fig. 1) . Comparison of the isatin and 1,4-diphenyl-2-butene structures shows that the side chain of Ile-199 exhibits differing rotamer conformations that function as a ''gate'' between the entrance and substrate cavities (Fig. 5) . When isatin is bound, the Ile-199 side chain separates the two cavities. When 1,4-diphenyl-2-butene is bound, the side chain is rotated to a conformation such that the two cavities are no longer separated and are now fused forming a single cavity. This finding of an MAO-B inhibitor that spans both cavities in binding demonstrates that new reversible inhibitors could be developed that would use both cavities as potential binding targets. Unpublished data in our laboratories have shown that trans-trans-1,4-diphenyl-1,3-butadiene binds to MAO-B with a higher affinity (K i ϭ 7 M). These diphenyl compounds exhibit high specificity for MAO-B (10 3 higher affinity for MAO-B compared with MAO-A) and therefore could represent lead compounds for the development of MAO-B inhibitors.
The concept of cavity-spanning ligands is further supported by analysis of the triclinic MAO-B crystals that were obtained by These studies, as well as spectral studies in our laboratory, show that inactivation of MAO-B by either inhibitor leads to a stable bleaching of the flavin absorption spectrum even in the presence of oxygen. However, in either case, such putative flavin adducts are expected to be labile because denaturation of either inhibited enzyme results in the reappearance of a spectrum characteristic of oxidized flavin. Flavin bleaching is also observed in the crystalline inhibited enzyme as measured by single-crystal microspectrophotometry (data not shown).
The structure of MAO-B after inhibition with N-(2-aminoethyl)-4-chlorobenzamide shows that the inhibitor is bound to the enzyme as a flavin N(5) adduct (Fig. 6) . The aromatic ring of the inhibitor adopts the same orientation and position as isatin. The resolution of the x-ray data cannot unambiguously determine the detailed molecular formula of this adduct, as shown in Fig. 7 . However, preliminary mechanistic studies of this inhibition suggest the amine nitrogen is released before forming the N(5) adduct. The structural data show that the Ile-199 side chain is in the same rotamer conformation exhibited by 1,4-diphenyl-2-butene such that the entrance and substrate cavities are fused. This change in conformation is necessary to accommodate the p-chloro substituent on the benzamide ring.
Structural data of MAO-B inhibited by 2-phenylcyclopropylamine show that this inhibitor binds to the flavin as a C(4a) adduct (Fig. 6) . The structure of this adduct differs from that formed with N-(2-aminoethyl)-4-chlorobenzamide not only in the flavin ring substitution site but also in the orientation of the phenyl ring, which is parallel to the flavin ring rather than perpendicular as found in all other complexes. To accommodate this ring orientation, Gln-206 must move Ϸ1 Å. The conformation of the phenyl ring of the tranylcypromine complex does not extend in the substrate cavity far enough to induce the rotamer conformation of Ile-199 to the open form. Thus, in this aspect, the tranylcypromine-inhibited form resembles that of isatininhibited MAO-B.
The electron density of the tranylcypromine-MAO-B complex is best fit with a structure in which the cyclopropyl ring is open (Figs. 6 and 7) . Formation of this flavin C(4a) adduct can be accommodated by a mechanism for inhibition similar to that shown by Sayre's laboratory for quinone-mediated oxidative cleavage of cyclopropylamines (19) . No extra electron density due to inhibitor binding was observed around Cys-365 (see ref. (20) . A second point to be made is that the peptide bond of the FAD-linking cysteinyl residue (Cys-397-Tyr-398) is in an energetically unfavorable cis rather than trans conformation. Structural analysis of MAO-B shows that this cis Cys-397-Tyr-398 peptide bond results in a favorable steric orientation of the phenolic ring of Tyr-398, which is a component of the active site (1) . Examination of structures of other flavoenzymes containing 8␣-covalent flavins shows only trans conformations of the C-terminal peptide linkage of the residue covalently bound to the flavin. Therefore, this cis linkage appears to be unique to MAO-B rather than a general feature associated with covalent binding of flavin coenzymes to proteins. cis Nonproline conformers are often found proximal to the functional sites of proteins (21) . This strained conformation of the Cys-397-Tyr-398 peptide bond in MAO-B adheres to that paradigm.
Another source of strain about the flavin site is the bent and twisted conformation of the normally flat aromatic isoalloxazine ring of the flavin cofactor (Fig. 6) . The angle between the dimethylbenzene ring and the pyrimidine ring is Ϸ30°. 5 . Isocontour of GRID molecular interaction fields computed with an aromatic sp 2 carbon probe (gray) and with a neutral NH2 probe (cyan). The contour encloses points with negative values under Ϫ2 kcal͞mol for the sp 2 carbon probe and Ϫ5 kcal͞mol for the NH2 probe. This picture was generated by using the coordinates from the 1,4-diphenyl-2-butene complex with MAO-B. The inhibitor is highlighted in dark gray ball-and-stick; the inhibitor ring in contact with Phe-103, Ile-199, and Ile-316 occupies the entrance cavity space, whereas the inhibitor ring in contact with Tyr-398 and Tyr-435 occupies the substrate cavity space (Fig. 1) . Atoms are colored as in Fig. 3 . The conformation of Ile-199 as observed in the isatin complex is shown in red to depict the conformational change in this residue that leads to merging of the two cavities, which is observed in the MAO-B complexes with N-(2-aminoethyl)-4-chlorobenzamide, 1,4-diphenyl-2-butene, or lauryldimethylamine N-oxide. phobic nature of the entrance and substrate cavities provides a structural rationale for this property. The energetics of an anionic species traversing these hydrophobic cavities are simply too formidable to overcome even though the flavin ring is in a conformation that readily would form such an adduct.
Conclusions Regarding the Active-Site Structure of MAO-B. By using the program GRID (13) , a picture of the inhibitor binding site for 1,4-diphenyl-2-butene can be viewed in regards to hydrophobicity and hydrophilicity. As seen in Fig. 5 , the major part of the cavity is hydrophobic, which allows for the tight binding of apolar substrates and inhibitors. The only hydrophilic section is near the flavin and is required for recognition and directionality of the substrate amine functionality. This hydrophilic region is located between Tyr-398 and Tyr-435, which, together with the flavin, form an aromatic cage for amine recognition (1, 20) . Mutagenesis studies targeting these Tyr side chains in both MAO-A and MAO-B support the key role of these residues in substrate binding (22) . We find several ordered, captive water molecules that fill in vacant space in the inhibitor binding cavity. Therefore, the design of future MAO-B inhibitors should consider hydrophilic substituents that could displace these ordered waters, resulting in an increased affinity and specificity. Another aspect emerging from this work are the subtle and inhibitor-dependent changes in conformation of residues in the binding cavity of MAO-B. These results are consistent with conclusions reached from quantitative structure-function activity relationship studies (23) and demonstrate that induced fit and active site plasticity are important components of MAO-B inhibition. 
